Viewing Study NCT07412756


Ignite Creation Date: 2026-03-26 @ 3:17 PM
Ignite Modification Date: 2026-03-29 @ 11:22 PM
Study NCT ID: NCT07412756
Status: RECRUITING
Last Update Posted: 2026-03-23
First Post: 2026-02-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Sponsor: Eli Lilly and Company
Organization:

Study Overview

Official Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD 1)
Status: RECRUITING
Status Verified Date: 2026-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: RENEW-MDD-1
Brief Summary: This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.

The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months. The duration of study participation may vary and may be shortened if depression symptoms worsen or if withdrawal from the study occurs for any reason.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2025-522308-25-00 CTIS None View
J2S-MC-GZMH OTHER Eli Lilly and Company View